Wells Fargo lowered the firm’s price target on Celldex (CLDX) to $38 from $44 and keeps an Overweight rating on the shares. Shares should be down 10%-15% on the failure in eosinophilic esophagitis, but he Street was not assigning much to this program, the analyst tells investors in a research note. The firm would buy shares on weakness.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex’s Promising Pipeline and Financial Stability Justify Buy Rating Despite Recent Setback
- Closing Bell Movers: La-Z-Boy down 24% after earnings miss
- Celldex down 12.5% at $21.01 after barzolvolimab study update
- Celldex Halts Barzolvolimab Development for EoE
- Celldex says barzolvolimab study meets primary endpoint, will not advance in EoE